DELRAY BEACH, Fla., Sept. 14, 2011 (GLOBE NEWSWIRE) -- PositiveID Corporation ("PositiveID" or the "Company") (OTCBB:PSID), a developer of medical technologies for diabetes management, clinical diagnostics and bio-threat detection, announced today that it is expanding its biological detection capabilities to include the detection of H5N1, or avian flu, amid signs that a mutant strain of the deadly bird flu virus is spreading overseas. Through its MicroFluidic Systems ("MFS") subsidiary, PositiveID has the biological capability to detect virtually any virus, bacteria or toxin in an environmental or clinical environment.
